Improving Insurance Coverage for RSV Vaccines

EP: 1.Overview of RSV Patient Populations

EP: 2.Complications Associated with RSV Infections

EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

EP: 4.RSV: Risk Factors and How It’s Spread

EP: 5.Diagnostic Practices for RSV

EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients

EP: 7.Shared Decision-Making Practices in RSV

EP: 8.Financial and Clinical Benefits of RSV Immunization

EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

EP: 10.Addressing Vaccine Fatigue

EP: 11.Identifying Patients Eligible for RSV Vaccine

EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines

Now Viewing

EP: 13.Improving Insurance Coverage for RSV Vaccines

EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation

EP: 15.Key Takeaways on RSV Vaccination

Video content above is prompted by the following questions:

• With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?
  • How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?
• How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?
  • How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?